Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019698 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775720 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775787 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL29355417 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL460037 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL1659938 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775723 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL18746282 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL460038 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL1660720 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8259555-A | — | — | None | — | — | JP | disclosed |
| US-11952358-B2 | Flavan-3-ol analogs and anti-inflammatory activity | HONG KONG BAPTIST UNIVERSITY (CN) | 2024-04-09 | — | — | US | disclosed |
| WO-2023230574-A1 | ENGINEERED PHENYLALANINE AMMONIA LYASE AND TYROSINE AMMONIA LYASE ENZYMES FOR PRODUCING AROMATIC COMPOUNDS | GINKGO BIOWORKS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | HONG KONG BAPTIST UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | HONG KONG BAPTIST UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | HONG KONG BAPTIST UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
| US-10308624-B2 | Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds | NORTHWESTERN UNIVERSITY (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308624-B2 | Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds | NORTHWESTERN UNIVERSITY (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180099943-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | NORTHWESTERN UNIVERSITY | 2018-04-12 | — | — | US | disclosed |
| US-20180099943-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | NORTHWESTERN UNIVERSITY | 2018-04-12 | — | — | US | disclosed |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013022846-A2 | FLAVONOID COMPOUNDS | CARDERO THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2488010-A1 | MANIPULATION OF FLAVONOID BIOSYNTHETIC PATHWAY | Agriculture Victoria Services Pty Ltd (AU) | 2012-08-22 | — | — | EP | disclosed |
| US-20120204289-A1 | Manipulation of flavonoid biosynthetic pathway | AGRICULTURE VICTORIA SERVICES PTY LTD. (AU) | 2012-08-09 | — | — | US | disclosed |
| WO-2011044632-A1 | MANIPULATION OF FLAVONOID BIOSYNTHETIC PATHWAY | AGRICULTURE VICTORIA SERVICES PTY LTD (AU) | 2011-04-21 | — | — | WO | disclosed |
| JP-H08259555-A | OPTICALLY ACTIVE TRANS-3-HYDROXYFLAVAN DERIVATIVE AND ITS PRODUCTION | KAWAKEN FINE CHEM CO LTD | 1996-10-08 | — | — | JP | disclosed |
| US-4935441-A | Flavene and thioflavene derivates, processes for their manufacture, pharmaceutical preparations that contain such compounds, and the use of the latter | ZYMA SA (CH) | 1990-06-19 | — | — | US | disclosed |
| EP-0139615-B1 | FLAVENE AND THIOFLAVENE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SUCH COMPOUNDS, AND THE USE OF THE LATTER | Zyma SA (CH) | 1989-04-19 | — | — | EP | disclosed |
| EP-0139615-A2 | Flavene and thioflavene derivatives, processes for their manufacture, pharmaceutical preparations that contain such compounds, and the use of the latter | Zyma SA (CH) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952358-B2 | Flavan-3-ol analogs and anti-inflammatory activity | IL1A, IL6, IL1B | CYP3A4 965/4885KDM4E 4013/4885HSD17B10 2219/4885 |
| US-20140256741-A1 | FLAVONOID COMPOUNDS | FIS1, TFAM, MFN2 | CYP3A4 3740/4885KDM4E 1854/4885HSD17B10 569/4885 |
| US-10308624-B2 | Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds | PNP, PPA1, CDS2 | CYP3A4 88/4885KDM4E 2162/4885HSD17B10 1564/4885 |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | IL1A, IL6, IL1B | CYP3A4 965/4885KDM4E 4013/4885HSD17B10 2219/4885 |
| US-20180099943-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | PNP, PPA1, CDS2 | CYP3A4 88/4885KDM4E 2162/4885HSD17B10 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.